VUB spin-off Precirix, a private, clinical-stage biotechnology company developing novel radiopharmaceuticals in oncology, announces the appointment of Dr. Niva Almaula, an experienced business development executive based in New York, as Chief Business Officer. In this role, Dr. Almaula will drive the company’s global business development strategy.